Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + AG in Perioperative Treatment of Pancreatic Cancer
NCT07277452Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in pancreatic cancer (PC), sponsored by Jiangsu Provincial People's Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07277452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07277452.